编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。作为全球规模最大、学术水平最高、最具权威性的国际肿瘤会议之一，2025年ASCO年会将汇聚顶级肿瘤专家、学者和行业领袖，共探肿瘤领域的前沿研究成果和先进治疗方法。
日前，2025 ASCO入选摘要标题（包括Late-Breaking Abstracts）已发布。摘要具体内容将在2025年5月22日发布，Late-breaking摘要内容将在会议当天发布。《肿瘤瞭望-血液时讯》特别整理血液肿瘤领域的重磅研究，包括1项LBA、27项口头报告、27项快速口头报告，助力大家提前了解会议的重磅内容。
01
Plenary Session
当地时间：6月1日13:00-16:00
报告地点：Hall B1
摘要号：LBA3
英文标题：Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV)
中文标题：：rusfertide治疗真性红细胞增多症（PV）的三期、双盲、安慰剂（PBO）对照VERIFY研究结果
讲者：Andrew Tucker Kuykendall, MD| Moffitt Cancer Center
02
Oral Abstract Session
淋巴瘤与慢性淋巴细胞白血病
当地时间：5月30日14:45–17:45
报告地点：S100a
摘要号：7000
英文标题：Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial
中文标题：通过PhasED-Seq对国家试验中DLBCL患者治疗结束ctDNA MRD的前瞻性验证
讲者：Steven Wang, MD | Amsterdam UMC Location Vrije Universiteit
摘要号：7001
英文标题：Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group
中文标题：自然杀伤性 T 细胞淋巴瘤分期系统修订：中国西南肿瘤学组及亚洲淋巴瘤研究组多中心研究
讲者：林桐榆（四川省肿瘤医院）
摘要号：7002
英文标题：Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses
中文标题：不同组织学分级滤泡性淋巴瘤的分子图谱：来自基因组和转录组分析的见解
讲者：孙聪（天津医科大学肿瘤医院）
摘要号：7003
英文标题：A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)
中文标题：KITE-363抗CD19/CD20嵌合抗原受体（CAR）T细胞治疗复发/难治性B细胞淋巴瘤患者的Ⅰ期临床研究
讲者：Saurabh Dahiya, MD, FACP | Stanford University School of Medicine
摘要号：7004
英文标题：Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma
中文标题：多病毒特异性T细胞用于增强双特异性抗体在淋巴瘤中的治疗活性
讲者：Akiva Diamond, MD | Department of Medicine, Section of Hematology-Oncology, Baylor College of Medicine; Baylor St.Luke’s Medical Center; Dan L Duncan Comprehensive Cancer Center
摘要号：7005
英文标题：WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma
中文标题：WaveLINE-003：zilovertamab vedotin联合标准治疗用于复发/难治性弥漫大B细胞淋巴瘤的Ⅱ/Ⅲ期临床试验
讲者：Philippe Armand, MD, PhD | Dana-Farber Cancer Institute
摘要号：7006
英文标题：Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial)
中文标题：信迪利单抗（抗PD-1抗体）联合西达本胺（一种口服HDACi）继以 P-GemOx 方案治疗初治结外自然杀伤性 /T 细胞淋巴瘤（TN-ENKTL）患者的多中心、开放标签、单臂、II 期研究（SCENT-2 试验）
讲者：黄慧强（中山大学肿瘤防治中心）
摘要号：7007
英文标题：Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21)
中文标题：信迪利单抗（抗PD-1）联合依托泊苷（ICE）方案用于二线治疗经典霍奇金淋巴瘤（cHL）：一项多中心、随机、对照、双盲 III 期研究（ORIENT-21）的结果
讲者：刘鹏（中国医学科学院肿瘤医院）
摘要号：7008
英文标题：Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)
中文标题：先天细胞接合剂acimtamig（AFM13）联合AlloNK（AB-101）治疗复发或难治性经典型霍奇金淋巴瘤的Ⅱ期临床试验剂量探索部分结果（LuminICE-203）
讲者：Joseph E. Maakaron, MD | Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota
白血病、骨髓增生异常综合征与异基因造血干细胞移植
当地时间：6月2日15:00-18:00
报告地点：S100a
摘要号：6500
英文标题：Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial
中文标题：Ropeginterferon alfa-2b vs. anagrelide治疗原发性血小板增多症：SURPASS-ET Ⅲ期临床试验的主要结果
讲者：Ruben A. Mesa, MD | Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine
摘要号：6501
英文标题：Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE)
中文标题：asciminib（ASC）vs. nilotinib（NIL）用于新诊断慢性期慢性粒细胞白血病（CML-CP）患者的不良事件导致治疗中断时间（TTDAE）:ASC4START Ⅲb期临床试验主要终点结果
讲者：Andreas Hochhaus, MD | Klinik für Innere Medizin II, Universitätsklinikum Jena
摘要号：6502
英文标题：Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study
中文标题：CADENZA研究中pivekimab sunirine（PVEK）治疗母细胞性浆细胞样树突状细胞肿瘤（BPDCN）患者的疗效与安全性
讲者：Naveen Pemmaraju, MD | The University of Texas MD Anderson Cancer Center
摘要号：6503
英文标题：Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes
中文标题：克拉屈滨、低剂量阿糖胞苷联合维奈克拉与阿扎胞苷联合维奈克拉交替治疗高危慢性粒单核细胞白血病和骨髓增生异常综合征的Ⅱ期临床研究
讲者：Guillermo Montalban-Bravo, MD | The University of Texas MD Anderson Cancer Center
摘要号：6504
英文标题：An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts
中文标题：全口服方案decitabine-cedazuridine（DEC-C）联合维奈克拉（VEN）用于不适合强化诱导化疗的新诊断急性髓系白血病（AML）患者：来自101例患者的Ⅱ期队列研究结果
讲者：Amer Methqal Zeidan, MBBS | Yale University School of Medicine
摘要号：6505
英文标题：Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies
中文标题：lisaftoclax（APG-2575）联合阿扎胞苷（AZA）治疗初治或既往接受过维奈克拉（VEN）治疗的髓系恶性肿瘤患者的Ⅰb/Ⅱ期临床研究
讲者：Michael Francis Leahy, FRACP, FRCP, FRCPath, MBChB | Royal Perth Hospital
摘要号：6506
英文标题：Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study
中文标题：Ziftomenib治疗复发/难治性（R/R）NPM1突变急性髓系白血病（AML）：关键KOMET-001研究中Ⅰb/Ⅱ期临床疗效和安全性结果
讲者：Eunice S. Wang, MD | Roswell Park Comprehensive Cancer Center
摘要号：6507
英文标题：γ9δ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION
中文标题：γ9δ2 T细胞激活（γδTCA）联合ICT01和阿扎胞苷-维奈克拉（AV）治疗高龄/unfit新诊断急性髓系白血病（AML）成年患者：EVICTION Ⅰ/Ⅱ期研究中的初步疗效和剂量选择
讲者：Pierre Yves Dumas, MD, PhD| CHU
摘要号：6508
英文标题：Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation
中文标题：接受异基因造血干细胞移植后存活超过2年患者的长期结局
讲者：Arjun Datt Law, MD, DM, MBBS, FCRP | Princess Margaret Cancer Centre
浆细胞病
当地时间：6月3日09:45-12:45
报告地点：S100bc
摘要号：7500
英文标题：MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial
中文标题：在适合移植的新诊断多发性骨髓瘤（NDMM）患者中，IsaKRD诱导后MRD驱动策略：MIDAS Ⅲ期临床试验的主要终点
讲者：Aurore Perrot, MD, PhD | Toulouse University, CHU Oncopole
摘要号：7501
英文标题：Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial
中文标题：皮下注射达雷妥尤单抗（Dara）+硼替佐米/来那度胺/地塞米松（VRd）联合达雷妥尤单抗+来那度胺（DR）维持治疗适合移植（TE）新诊断多发性骨髓瘤（NDMM）患者：PERSEUS Ⅲ期临床试验中持续微小残留病（MRD）阴性的分析
讲者：Philippe Moreau, MD, PhD | University Hospital Hôtel-Dieu
摘要号：7502
英文标题：Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)
中文标题：卡非佐米-来那度胺-地塞米松联合或不联合艾沙妥昔单抗（Isatuximab）治疗新诊断多发性骨髓瘤患者：Ⅲ期IsKia临床试验中的持续微小残留病（MRD）阴性分析
讲者：Francesca Gay, MD, PhD | Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino
摘要号：7503
英文标题：Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial
中文标题：卡非佐米、来那度胺和地塞米松（KRd）联合或不联合达雷妥尤单抗（D）治疗新诊断多发性骨髓瘤（NDMM）患者的随机多中心研究：ADVANCE临床试验
讲者：Carl Ola Landgren, MD, PhD | Myeloma Program and Experimental Therapeutics Program, University of Miami
摘要号：7504
英文标题：Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1
中文标题：Elranatamab联合达雷妥尤单抗和来那度胺（EDR）治疗不适合接受移植的新诊断多发性骨髓瘤（NDMM）患者：MagnetisMM-6 part 1的初步结果
讲者：HANG QUACH, MD, FRACP, FRCPA | St Vincent’s Hospital Melbourne, University of Melbourne
摘要号：7505
英文标题：First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results
中文标题：JNJ-79635322（JNJ-5322）新型三特异性抗体（TsAb）在复发/难治性多发性骨髓瘤（RRMM）患者中的首次人体研究：初步Ⅰ期结果
讲者：Niels W.C.J. van de Donk, MD, PhD | Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology
摘要号：7506
英文标题：Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study
中文标题：艾沙妥昔单抗（Isa）通过体外输送系统（OBDS）皮下（SC）给药vs. Isa静脉注射（IV），联合泊马度胺和地塞米松（Pd）治疗复发/难治性多发性骨髓瘤（RRMM）：随机非劣效性Ⅲ期IRAKLIA研究结果
讲者：Xavier P. Leleu, MD, PhD | Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402
摘要号：7507
英文标题：Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)
中文标题：CARTITUDE-1研究中接受ciltacabtagene autoleucel（cilta-cel）治疗的复发/难治性多发性骨髓瘤（RRMM）患者的长期（≥5年）缓解与生存情况
讲者：Peter M. Voorhees, MD | Atrium Health / Levine Cancer Institute, Wake Forest University School of Medicine
摘要号：7508
英文标题：Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201
中文标题：Nexicart-2的安全性与疗效数据：CAR-T在R/R轻链淀粉样变中的首次美国试验（Nxc-201）
讲者：Heather Jolie Landau, MD | Memorial Sloan Kettering Cancer Center
03
Rapid Oral Abstract Session
白血病、骨髓增生异常综合征与异基因造血干细胞移植
当地时间：5月30日13:00-14:30
报告地点：E450a
摘要号：6509
英文标题：A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults
中文标题：asciminib联合达沙替尼、泼尼松和贝林妥欧单抗治疗成人Ph阳性急性白血病的Ⅰ期临床研究
讲者：Marlise R Luskin, MD | Dana-Farber Cancer Institute
摘要号：6510
英文标题：MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis
中文标题：PhALLCON Ⅲ期临床试验中诱导治疗结束后的MRD阴性率：事后分析
讲者：Ibrahim Aldoss, MD | City of Hope – Duarte
摘要号：6511
英文标题：Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation
中文标题：减量PTCy用于接受配型无关供者异基因造血干细胞移植的急性髓系白血病患者
讲者：Nihar Desai, MD, DM | Princess Margaret Hospital
摘要号：6512
英文标题：Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial
中文标题：COMMANDS研究中luspatercept（LUSPA）对比促红素α（epoetin alfa，EA）治疗未使用促红素治疗的极低、低或中危骨髓增生异常综合征（MDS）患者的总体生存期（OS）与获得输血独立（TI）后反应持续时间分析
讲者：Guillermo Garcia-Manero, MD | University of Texas MD Anderson Cancer Center
摘要号：6513
英文标题：Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study
中文标题：bexmarilimab联合阿扎胞苷抑制巨噬细胞检查点Clever-1治疗骨髓增生异常综合征的疗效：BEXMAB Ⅰ/Ⅱ期研究结果
讲者：Naval Guastad Daver, MD | Department of Leukemia, The University of Texas MD Anderson Cancer Center
摘要号：6514
英文标题：Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML
中文标题：地西他滨和维奈克拉用于诱导终末分化，以改善TP53突变型MDS和AML的治疗结局
讲者：Mendel Goldfinger, MD | Montefiore Einstein Comprehensive Cancer Center
摘要号：6515
英文标题：IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF)
中文标题：IMproveMF更新：imetelstat（IME）联合芦可替尼（RUX）治疗中危1（INT-1）、中危2（INT-2）或高危（HR）骨髓纤维化（MF）患者的Ⅰ/Ⅰb期临床试验
讲者：John Mascarenhas, MD | Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
摘要号：6516
英文标题：Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial
中文标题：asciminib（ASC）治疗接受过1种酪氨酸激酶抑制剂（TKI）治疗的慢性期慢性髓性白血病（CML-CP）患者的疗效和安全性：Ⅱ期ASC2ESCALATE试验的中期分析（IA）
讲者：David Jacob Andorsky, MD | Rocky Mountain Cancer Centers, US Oncology Research
摘要号：6517
英文标题：Age-related macular degeneration in individuals with clonal hematopoiesis
中文标题：克隆性造血个体的年龄相关性黄斑变性
讲者：Keishla Marie Arce-Ruiz, BS | McGraw/Patterson Center for Population Sciences, Dana-Farber Cancer Institute
淋巴瘤与慢性淋巴细胞白血病
当地时间：5月31日08:00-09:30
报告地点：E450a
摘要号：7009
英文标题：Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D
中文标题：zanubrutinib（zanu）联合维奈克拉（ven）治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）：SEQUOIA研究D组结果
讲者：Mazyar Shadman, MD, MPH | Fred Hutchinson Cancer Center and University of Washington
摘要号：7010
英文标题：Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders
中文标题：DZD8586 在经共价或非共价 BTK 抑制剂及 BTK 降解剂治疗后的 CLL/SLL 患者中的I/II期研究
讲者：李建勇（江苏省人民医院）
摘要号：7011
英文标题：SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
中文标题：SEQUOIA研究5年随访，C组：前线zanubrutinib单药治疗del(17p)及未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者
讲者：Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS | Alfred Hospital and Monash University
摘要号：7012
英文标题：A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma
中文标题：一项1/2期研究：评估选择性 EZH2 抑制剂 XNW5004 在复发/难治性非霍奇金淋巴瘤患者中的安全性与有效性
讲者：邱录贵[中国医学科学院血液病医院（中国医学科学院血液学研究所）]
摘要号：7013
英文标题：CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study
中文标题：以 CD79b 为靶点的抗体偶联药物（ADC）SHR - A1912 联合R - GemOx方案用于复发 / 难治性（R/R）弥漫性大 B 细胞淋巴瘤（DLBCL）患者的1b/2期研究数据
讲者：李亚军（湖南省肿瘤医院）
摘要号：7014
英文标题：Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study
中文标题：固定疗程皮下（SC）莫妥珠单抗（Mosun）治疗既往未治疗的高肿瘤负担滤泡性淋巴瘤（FL）患者：Ⅱ期MorningSun研究的中期结果
讲者：Ian W. Flinn, MD, PhD | Tennessee Oncology and OneOncology
摘要号：7015
英文标题：Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO
中文标题：格菲妥单抗联合吉西他滨和奥沙利铂（Glofit-GemOx）治疗复发/难治性（R/R）弥漫大B细胞淋巴瘤（DLBCL）患者：STARGLO研究2年随访结果
讲者：Jeremy S. Abramson, MD | Massachusetts General Hospital Cancer Center
摘要号：7016
英文标题：Worldwide experience of chronic active EBV infection: Retrospective cohort study
中文标题：全球慢性活动性EBV感染经验：回顾性队列研究
讲者：王欣然（华中科技大学同济医学院附属同济医院）
摘要号：7017
英文标题：Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study
中文标题：伊布替尼联合维奈克拉一线治疗年龄较大或存在TP53突变的套细胞淋巴瘤（MCL）患者的疗效和安全性：SYMPATICO研究
讲者：Michael Wang, MD | Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
创新性治疗—免疫疗法
当地时间：6月1日11:15-12:45
报告地点：S406
摘要号：2514
英文标题：Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL)
中文标题：靶向CCR8抗体治疗复发/难治性皮肤T细胞淋巴瘤（R/R CTCL）的Ⅰ期临床试验剂量递增阶段初步结果
讲者：李志铭（中山大学肿瘤防治中心）
浆细胞病
当地时间：6月2日08:00-09:30
报告地点：E450b
摘要号：7509
英文标题：Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial
中文标题：艾沙妥昔单抗、卡非佐米、来那度胺和地塞米松（Isa-KRd）治疗高危（HR）新诊断多发性骨髓瘤（NDMM）：GMMG-CONCEPT研究中适合移植（TE）患者全队列的首次报告
讲者：Lisa B. Leypoldt, MD | University Medical Center Hamburg-Eppendorf
摘要号：7510
英文标题：Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial
中文标题：Linvoseltamab（LINVO）联合硼替佐米（BTZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的首次结果
讲者：Xavier P. Leleu, MD, PhD | Hematology, CIC 1082, U1313, CHU, University
摘要号：7511
英文标题：Heterogeneity in the expression of GPRC5D between patients with multiple myeloma
中文标题：多发性骨髓瘤患者中GPRC5D表达的异质性
讲者：Harsh Parmar | John Theurer Cancer Center, Hackensack University Medical Center
摘要号：7512
英文标题：Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial
中文标题：Belantamab mafodotin联合来那度胺/地塞米松治疗新诊断的中度fit和虚弱多发性骨髓瘤患者：来自Ⅰ/Ⅱ期BELARD临床试验的长期疗效和安全性结果
讲者：Evangelos Terpos, MD, PhD | Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine
摘要号：7513
英文标题：Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial
中文标题：Linvoseltamab（LINVO）联合卡非佐米（CFZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的初步结果
讲者：Salomon Manier, MD, PhD | Hematology Department, Lille University Hospital
摘要号：7514
英文标题：Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results
中文标题：ISB 2001的Ⅰ期首次人体研究：一种针对BCMAxCD38xCD3的三特异性抗体治疗复发/难治性多发性骨髓瘤（RRMM）患者——剂量递增（DE）结果
讲者：Eben I. Lichtman, MD | UNC Lineberger Comprehensive Cancer Center
摘要号：7515
英文标题：Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial
中文标题：belantamab mafodotin联合泊马度胺和地塞米松（BPd）与泊马度胺、硼替佐米和地塞米松（PVd）治疗复发/难治性多发性骨髓瘤（RRMM）患者的微小残留病（MRD）阴性率比较：来自DREAMM-8研究的分析
讲者：Suzanne Trudel, MD | Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre
摘要号：7516
英文标题：Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study
中文标题：达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松（DVRd）治疗新诊断多发性骨髓瘤（NDMM）患者：Ⅲ期CEPHEUS研究中不适合移植（TIE）患者的亚组分析
讲者：Saad Z Usmani, MD, MBA, FRCP, FASCO | Memorial Sloan Kettering Cancer Center